ALCAR.PA Carmat SA EURONEXT market closed 29 Jan 2026: Oversold bounce at €0.099
ALCAR.PA stock closed at €0.099 on EURONEXT on 29 Jan 2026, marking a lower-range finish after heavy selling. The share traded between €0.097 and €0.110 on volume of 807,348, roughly in line with average volume of 797,166. Fundamentals remain weak with EPS -1.15 and a negative PE, but the share is technically oversold versus its 50-day average €0.148 and 200-day average €0.595. We see a defined oversold bounce setup for Carmat SA (ALCAR.PA) that may offer short-term trading opportunities, while broader healthcare sector trends remain mixed in Europe.
ALCAR.PA stock technicals and volume
Price action closed at €0.099 on EURONEXT after intraday range €0.097–€0.110, giving a relative volume of 1.01x. The 50-day average price is €0.14751 and the 200-day average is €0.59472, so the stock sits well below both moving averages. The short-term setup shows oversold conditions and higher-than-average selling in recent months, creating a possible mean-reversion bounce if buyers return near support around €0.09–€0.10.
Fundamentals: earnings, ratios and balance sheet
Carmat SA reports EPS -1.15 and a negative PE (around -0.09), reflecting ongoing losses and development spending. Market cap stands at €6,361,146 with 64,254,002 shares outstanding. Key ratios show a current ratio of 1.70 and cash per share €0.206, indicating limited short-term liquidity while the enterprise value to sales is elevated at 8.49x. These metrics underline execution risk despite technology potential.
Meyka AI rates ALCAR.PA with a score out of 100
Meyka AI rates ALCAR.PA with a score out of 100: 68.92 (B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects a weak valuation but some recovery potential; these grades are model outputs and not personalized investment advice.
Catalysts, risks and sector context
Near-term catalysts include the next earnings announcement on 18 Feb 2026 and any operational updates on clinical or supply activity. Sector-wide, European healthcare performance is modest year-to-date and averages higher ROE than Carmat’s current metrics, which can limit upside without clear progress. Key risks are continued cash burn, regulatory milestones, and limited free-float liquidity that can amplify volatility.
Price action scenarios and price targets
For an oversold bounce trade we outline a near-term target at €0.18 with a stop under €0.085; this implies an upside of 81.82% from €0.099. A constructive multi-month recovery target aligns with the 200-day mean near €0.60, implying 506.06% upside, but that scenario requires clear operational improvement and funding. Use tight position sizing: the security is high risk and highly volatile.
Trading strategy and analyst consensus
Short-term traders can consider size-limited long positions on volume-backed bounces above €0.11 and trim near €0.18. Fundamental investors should wait for clearer financial improvement and reduced cash burn. Consensus coverage is thin and external analyst ratings skew bearish; monitor liquidity, clinical news, and funding updates before scaling exposure.
Final Thoughts
ALCAR.PA stock closed the session at €0.099 on EURONEXT on 29 Jan 2026, leaving a clear oversold bounce setup for traders who accept high risk. The company shows weak fundamentals — EPS -1.15, negative PE and limited market cap €6,361,146 — but technical oversold conditions and near-term catalysts create defined trade entry and exit points. Meyka AI’s forecast model projects a short-term bounce to €0.18 (implied upside 81.82%) and a constructive 12-month scenario to €0.60 (implied upside 506.06%). Forecasts are model-based projections and not guarantees. For investors we recommend strict risk limits, monitor the 18 Feb 2026 earnings date, and follow company updates on clinical progress. For further data see Carmat’s site and the market comparison on Investing.com for volume and peer context. Meyka AI, our AI-powered market analysis platform, flags this as a high-risk oversold opportunity rather than a buy recommendation.
FAQs
What is the current price and short-term outlook for ALCAR.PA stock?
ALCAR.PA stock closed at €0.099 on 29 Jan 2026. Short-term outlook is an oversold bounce target near €0.18 if buying returns; maintain tight stops due to high volatility.
How does Carmat’s financial health affect the ALCAR.PA stock outlook?
Carmat shows negative EPS -1.15, limited cash per share €0.206, and high enterprise value to sales, increasing funding and execution risk and limiting long-term upside until metrics improve.
What trading strategy suits the oversold bounce setup in ALCAR.PA?
Use small position sizes, enter on volume-supported bounces above €0.11, set a stop below €0.085, and target €0.18 for short-term trades while monitoring news and liquidity.
Where can I find official company updates for Carmat?
Company updates are available on Carmat’s official website and regulatory filings. For trading context check the market comparison on Investing.com and Carmat’s investor pages.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
